Precision in Practice: A Critical Overview of Recent Advances in Nasopharyngeal Cancer Management

Outcomes for patients with nasopharyngeal carcinoma (NPC) have improved significantly due to advances in radiation therapy technology, such as precision image guided intensity modulated radiation therapy, the emergence of novel systemic agents, and a growing understanding of disease biology and clinical behavior. Minimizing treatment-related toxicities while maintaining effective disease control is increasingly important in NPC, especially given its predilection for younger middle-aged patients with a long life expectancy after the cure of their disease. Over the past 5 years, multiple clinical trials and large contemporary series have offered valuable insights into optimizing treatment strategies that balance oncologic efficacy with functional preservation, positioning NPC as one of the most rapidly evolving head and neck cancer sites in the pursuit of precision oncology. This critical review summarizes data from randomized clinical trials, with a particular emphasis on studies published in the past 6 years, across 5 key areas: (1) treatment deintensification for low-risk disease; (2) strategies to improve treatment tolerability during the concurrent phase; (3) intensified treatment approaches for locoregionally advanced NPC; (4) utility of plasma Epstein-Barr virus DNA for treatment personalization; (5) tailored radiation therapy target volume delineation and organ-at-risk sparing; and (6) management strategies for recurrent and metastatic NPC. Together, these developments reflect a paradigm shift toward increasingly personalized, risk-adapted management of NPC that prioritizes both survival and quality of life.